Method for preventing and / or treating ocular conditions
By implanting a core containing ethylene-vinyl acetate copolymer in the supramolecular cavity, the problems of low delivery efficiency and blood-retinal barrier obstruction are solved, and the controlled release of therapeutic agents and efficient arrival of the choroidal agent is achieved. It is suitable for Treatment of eye diseases.
Patent Information
- Application Number
- CN202380030159.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-24
- Filing Date
- 2023-01-20
- Publication Date
- 2024-11-12
AI Technical Summary
Traditional intravitreal injections are inefficient and uncontrollable when delivering drugs to the posterior segment of the eye, which may lead to side effects, and the blood-retinal barrier prevents drug transport to the choroid and retinal pigment epithelium.
The implantable device is used to insert into the suprachoroidal cavity, and the core contains the dispersed therapeutic agent ethylene-vinyl acetate copolymer, which achieves controlled release of the therapeutic agent by controlling the core material and construction.
Effectively release therapeutic agents for extended periods, reduce side effects, and improve the efficiency of drugs reaching the choroid. It is suitable for preventing and treating eye diseases.
Smart Images

Figure CN118946333A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application is based upon and claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 302,300, filed on January 24, 2022, which is incorporated herein by reference. Background Art
[0003] Due to biodistribution, tissue penetration and pharmacokinetics, the efficacy of intravitreal injections for treating eye disorders is limited. Although therapeutic agents may have a variety of benefits, it is still difficult to deliver these compounds to the posterior segment of the eye in a controlled manner over a sustained period of time. Traditional intravitreal injections have been used to deliver drugs to the posterior segment of the eye, however, intravitreal injected drugs diffuse isotropically through the vitreous body and may diffuse toward non-targeted areas of the eye (e.g., lens and ciliary body). This may lead to undesirable side effects, such as 1) small molecules are rapidly distributed through the vitreous body or 2) macromolecules are more restricted and distributed more slowly. In addition, the blood-retinal barrier can hinder the transport of drugs from the vitreous body to the choroid and retinal pigment epithelium. The suprachoroidal space is located between the sclera and the choroid, extending from the anterior segment of the eye near the ciliary body to the posterior end of the eye near the optic nerve. The suprachoroidal space can be an alternative route for delivering therapeutic agents with various molecular weights. Therefore, there is still a need for improved methods for delivering therapeutic agents to the suprachoroidal space to prevent and / or treat eye disorders in patients. Summary of the invention
[0004] According to one embodiment of the present disclosure, a method for preventing and / or treating an ocular condition is disclosed. The method comprises inserting an implantable device into the suprachoroidal space of a patient, the implantable device comprising a core defining a peripheral surface, wherein the core comprises a core polymer matrix in which a therapeutic agent is dispersed. In addition, the core polymer matrix comprises ethylene-vinyl acetate copolymer.
[0005] Other features and aspects of the present invention are described in more detail below. BRIEF DESCRIPTION OF THE DRAWINGS
[0006] A complete and enabling disclosure of the present disclosure including the best mode of implementation known to one of ordinary skill in the art is more particularly set forth in the remainder of the specification with reference to the accompanying drawings, in which:
[0007] Figure 1 is a perspective view of one embodiment of an implantable device of the present invention;
[0008] Figure 2 yes Figure 1 A cross-sectional view of an implantable device;
[0009] Figure 3 is a perspective view of one embodiment of an implantable device of the present invention; and
[0010] Figure 4 yes Figure 3 Cross-sectional view of an implantable device.
[0011] In the present specification and drawings, repeated use of reference characters is intended to represent the same or analogous features or elements of the present invention. DETAILED DESCRIPTION
[0012] Those skilled in the art will appreciate that the discussion herein is merely to describe exemplary embodiments and is not intended to limit the broader aspects of the invention.
[0013] In general, the present invention relates to a method for preventing and / or treating an ocular condition, the method comprising inserting an implantable device into the suprachoroidal space of a patient (e.g., a human, a pet, a livestock, a racehorse, etc.). The term "suprachoroidal space" refers to the potential space between the sclera and the choroid. The method may be particularly suitable for treating ocular conditions, including age-related macular degeneration, inflammatory ocular conditions, and / or ocular conditions caused by or associated with infection or autoimmune diseases. Non-limiting examples of inflammatory ocular conditions that can be treated using the methods of the present invention include choroiditis, episcleritis, sarcoidosis, scleritis, ocular cicatricial pemphigoid, orbital inflammatory syndrome (e.g., orbital myositis, orbital pseudotumor, etc.), uveitis, infectious corneal ulcers, endophthalmitis, keratitis, conjunctivitis, thyroid eye disease, etc.
[0014] The manner in which the device of the present invention is implanted into the patient's eye can vary, as known to those skilled in the art. For example, the device can be inserted into the anterior segment (the anterior chamber between the posterior surface of the cornea and the iris and / or the posterior chamber between the iris and the front of the vitreous body), the posterior segment (e.g., the anterior transparent membrane, the vitreous body, the retina, the choroid, etc.), or a combination thereof. In some embodiments, the implantable device is inserted into the suprachoroidal space of the eye. When treating an eye disorder, it may be desirable to deliver the implantable device to the suprachoroidal space to avoid having to cross the blood-aqueous barrier.
[0015] Choroidal space injection techniques are well known and may include, for example, the use of a hollow needle through which the implant passes. Choroidal space may be entered or exposed by surgery (e.g., sclerotomy). For example, an implantable device may be inserted into the choroidal space by sclerotomy (e.g., cutting through the patient's sclera). For example, the patient's sclera is cut to form a scleral incision exposing the choroidal space. An implantable device may be delivered or inserted into the choroidal space by a suitable needle (e.g., a small needle or microneedle) through a scleral incision. The needle may have a small diameter size (e.g., a 18-gauge to 30-gauge needle) so that the incision is self-sealing and implantation occurs in a closed chamber. A self-sealing incision may also be formed using conventional "tunnel" surgery, in which a scraper-shaped scalpel is used to form a roughly inverted V-shaped incision in the cornea. In a preferred embodiment, the instrument used to form an incision in the cornea remains in place (i.e., extends through the corneal incision) during surgery and is not removed until implantation. This incision forming instrument can be used to place an ocular implant, or it can also cooperate with a delivery instrument to allow implantation through the same incision without removing the incision forming instrument. Of course, in other modes, various surgical instruments can pass through one or more corneal incisions multiple times.
[0016] The implantable device comprises a core that limits the peripheral surface. By selectively controlling the specific materials used to form the core and the specific way to construct them, the release rate of the therapeutic agent can be controlled over an extended period of time. More specifically, the core contains one or more layers of therapeutic agents dispersed in the core polymer matrix. The core polymer matrix includes one or more ethylene-vinyl acetate copolymers. The therapeutic agent can be present in the core with a relatively high load, for example, accounting for about 20wt.% to about 70wt.% of the core, about 25wt.% to about 65wt.% in some embodiments, about 30wt.% to about 60wt.% in some embodiments, and about 35wt.% to about 55wt.% in some embodiments. The polymer matrix can similarly account for about 30wt.% to about 80wt.% of the core, about 35wt.% to about 80wt.% in some embodiments, about 40wt.% to about 70wt.% in some embodiments, and about 45wt.% to about 65wt.% in some embodiments.
[0017] The resulting device can effectively continue to release therapeutic agents in the eye over an extended period of time. For example, an implantable device can release therapeutic agents in about 5 days or longer, about 20 days or longer in some embodiments, about 30 days or longer in some embodiments, about 60 days or longer in some embodiments, about 90 days or longer in some embodiments, about 120 days to about 360 days (for example, about 180 days) in some embodiments, about 361 days or longer in some embodiments. In addition, therapeutic agents can be released in a controlled manner (for example, zero order or near zero order) during the release time period. After a 30-day period, for example, the cumulative release rate of an implantable device can be about 20% to about 70%, about 30% to about 65% in some embodiments, and about 40% to about 60% in some embodiments. Similarly, after a 60-day period, the cumulative release rate of an implantable device can still be about 40% to about 85%, about 50% to about 80% in some embodiments, and about 60% to about 80% in some embodiments. The "cumulative release rate" can be determined by dividing the amount of therapeutic agent released over a specific time interval by the total amount of therapeutic agent initially present and then multiplying that number by 100.
[0018] Of course, the actual dosage level of the therapeutic agent delivered will vary according to the specific therapeutic agent used and the time period of its expected release. The dosage level is usually high enough to provide a therapeutically effective amount of steroidal agents that produce the desired therapeutic result, that is, the level or amount of the symptoms of the disease of the subject to be administered that is effectively reduced or alleviated. More specifically, as used herein, the phrase "therapeutically effective amount" refers to the dosage of the therapeutic agent that causes detectable improvement in one or more symptoms or indications of inflammatory eye diseases, or the dosage of the therapeutic agent that inhibits, prevents, alleviates or delays the progression of inflammatory eye diseases. Among other factors, the exact amount required will vary according to the age and overall condition of the subject to be treated, the ability of the subject's immune system, the desired degree of effect, the severity of the disease treated, the selected specific therapeutic agent and the mode of administration of the composition. In one embodiment, for example, the therapeutically effective amount can be about 5 μg to about 100 mg, about 0.1 mg to about 5 mg in some embodiments, and about 15 mg to about 90 mg, about 25 mg to about 75 mg, about 30 mg to about 60 mg in some embodiments. In some embodiments, the therapeutic agent can be released from the implantable device in a therapeutically effective amount to deliver about 0.05 mg / day to about 0.2 mg / day, for example, about 0.1 mg / day to about 0.15 mg / day, or any effective dose therebetween to prevent and / or treat ocular disorders. The amount of the therapeutic agent contained in an individual dose can be expressed in milligrams of the drug per kilogram of patient body weight (i.e., mg / kg). For example, the therapeutic agent can be administered to the patient at a dosage of about 0.0001 mg / kg to about 10 mg / kg of patient body weight.
[0019] Various embodiments of the present invention will now be described in further detail.
[0020] I. Core
[0021] A. Polymer Matrix
[0022] As described above, the core polymer matrix contains at least ethylene-vinyl acetate copolymer, which is generally derived from at least one ethylene monomer and at least one vinyl acetate monomer. Certain aspects of the copolymer can be selectively controlled to help achieve the desired release properties. For example, the vinyl acetate content of the copolymer can be selectively controlled in the range of about 10 wt.% to about 60 wt.%, in some embodiments about 20 wt.% to about 60 wt.%, in some embodiments about 25 wt.% to about 55 wt.%, in some embodiments about 30 wt.% to about 50 wt.%, in some embodiments about 35 wt.% to about 48 wt.%, and in some embodiments 38 wt.% to about 45 wt.%. Conversely, the ethylene content of the copolymer can similarly be in the range of about 40 wt.% to about 80 wt.%, 45 wt.% to about 75 wt.%, in some embodiments about 50 wt.% to about 80 wt.%, in some embodiments about 52 wt.% to about 65 wt.%, and in some embodiments about 55 wt.% to about 62 wt.%. Such a comonomer content can help achieve, among other things, a controlled, sustained release profile of the therapeutic agent while also having a relatively low melting temperature that is more similar in nature to the melting temperature of the therapeutic agent. The ethylene-vinyl acetate copolymer and the resulting polymer matrix can also have a melt flow index of about 0.2 g / 10 min to about 400 g / 10 min, in some embodiments 1 g / 10 min to about 200 g / 10 min, in some embodiments about 5 g / 10 min to about 90 g / 10 min, in some embodiments about 10 g / 10 min to about 80 g / 10 min, and in some embodiments about 30 g / 10 min to about 70 g / 10 min, as determined according to ASTM D1505-18 at a temperature of 190° C. and a load of 2.16 kg. The ethylene-vinyl acetate copolymer can also have a density of about 0.900 g / cm 3 (g / cm 3 ) to about 1.00g / cm 3 , in some embodiments about 0.910 g / cm 3 To about 0.980g / cm 3 , and in some embodiments about 0.940 g / cm 3To about 0.970g / cm 3 . For example, as determined according to ASTM D3418-15, the melting temperature of ethylene-vinyl acetate copolymers may similarly be from about 20° C. to about 70° C., in some embodiments from about 25° C. to about 65° C., and in some embodiments from about 30° C. to about 60° C. Particularly suitable examples of ethylene-vinyl acetate copolymers that may be employed include those known under the names Those obtained from Celanese (e.g., 4030AC); by name Those obtained from DuPont (e.g. 40W); and Those available from Arkema (eg, EVATANE 40-55).
[0023] In certain embodiments, it may also be desirable to employ blends of ethylene-vinyl acetate copolymers and hydrophobic polymers (described in more detail below) such that the overall blend and polymer matrix have a melting temperature and / or melt flow index within the above ranges. For example, the core polymer matrix may comprise a first ethylene-vinyl acetate copolymer and a second ethylene-vinyl acetate copolymer having a melting temperature greater than the melting temperature of the first copolymer. The second copolymer may similarly have a melt flow index that is the same, lower, or higher than the melt flow index of the corresponding first copolymer. For example, the first copolymer may have, for example, a melting temperature of about 20° C. to about 60° C., in some embodiments about 25° C. to about 55° C., and in some embodiments about 30° C. to about 50° C., as measured according to ASTM D3418-15; and / or a melt flow index of about 40 g / 10 min. to about 900 g / 10 min., in some embodiments about 50 g / 10 min. to about 500 g / 10 min., and in some embodiments about 55 g / 10 min. to about 250 g / 10 min., as measured according to ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kg. The second copolymer may similarly have, for example, a melting temperature of about 50° C. to about 100° C., in some embodiments about 55° C. to about 90° C., and in some embodiments about 60° C. to about 80° C. as measured according to ASTM D3418-15; and / or a melt flow index of about 0.2 g / 10 min. to about 55 g / 10 min., in some embodiments about 0.5 g / 10 min. to about 50 g / 10 min., and in some embodiments about 1 g / 10 min. to about 40 g / 10 min. as measured according to ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kg. The first copolymer may comprise from about 20 wt.% to about 80 wt.%, in some embodiments from about 30 wt.% to about 70 wt.%, and in some embodiments from about 40 wt.% to about 60 wt.%, of the polymer matrix, and the second ethylene copolymer may similarly comprise from about 20 wt.% to about 80 wt.%, in some embodiments from about 30 wt.% to about 70 wt.%, and in some embodiments from about 40 wt.% to about 60 wt.% of the polymer matrix. Blends of ethylene-vinyl acetate copolymers with other types of hydrophobic polymers may also be used, such as described below.
[0024] As is known in the art, ethylene-vinyl acetate copolymers having desired properties may generally be formed using any of a variety of techniques. In one embodiment, the polymer is prepared by copolymerizing ethylene monomer and vinyl acetate monomer in a high pressure reaction. Vinyl acetate may be prepared by oxidation of butane to produce acetic anhydride and acetaldehyde, which may be reacted together to form ethylene diacetate. Ethylene diacetate may then be thermally decomposed in the presence of an acid catalyst to form vinyl acetate monomer. Examples of suitable acid catalysts include aromatic sulfonic acids (e.g., benzenesulfonic acid, toluenesulfonic acid, ethylbenzenesulfonic acid, xylenesulfonic acid, and naphthalenesulfonic acid), sulfuric acid, and alkanesulfonic acids, such as Oxley et al. U.S. Patent No. 2,425,389; Schnizer U.S. Patent No. 2,859,241; and Isshiki et al. Vinyl acetate monomer can also be prepared by reacting acetic anhydride with hydrogen instead of acetaldehyde in the presence of a catalyst. This method converts directly from acetic anhydride and hydrogen to vinyl acetate without producing ethylene diacetate. In another embodiment, vinyl acetate monomer can be prepared by reacting acetaldehyde with ketene in the presence of a suitable solid catalyst such as a perfluorosulfonic acid resin or a zeolite.
[0025] In some cases, ethylene-vinyl acetate copolymers constitute the entire polymer content of the polymer matrix. However, in other cases, it may be desirable to include other polymers, such as other hydrophobic polymers and / or hydrophilic polymers described in more detail below. When used, it is generally desirable that such other polymers account for about 0.001wt.% to about 30wt.% of the polymer content of the polymer matrix, about 0.01wt.% to about 20wt.% in some embodiments, and about 0.1wt.% to about 10wt.% in some embodiments. In this case, ethylene-vinyl acetate copolymers can account for about 70wt.% to about 99.999wt.% of the polymer content of the polymer matrix, about 80wt.% to about 99.99wt.% in some embodiments, and about 90wt.% to about 99.9wt.% in some embodiments.
[0026] If desired, the core polymer matrix can also contain one or more plasticizers to help reduce the processing temperature, thereby allowing the use of a higher melting point copolymer and the therapeutic agent can not be degraded. Suitable plasticizers can include, for example, fatty acids, fatty acid esters, fatty acid salts, fatty acid amides, organic phosphates, hydrocarbon waxes, etc., and mixtures thereof. Fatty acids can generally be carbon chain lengths of about 8 to 22 carbon atoms, and in some embodiments, any saturated or unsaturated acid of about 10 to about 18 carbon atoms. If desired, acid can be substituted. Suitable fatty acids can include, for example, lauric acid, myristic acid, behenic acid, oleic acid, palmitic acid, stearic acid, ricinoleic acid, capric acid, neodecanoic acid, hydrogenated tallow fatty acids, hydroxystearic acid, hydrogenated castor oil, erucic acid, coconut oil fatty acids, etc., and mixtures thereof. Fatty acid derivatives can also be used, for example: fatty acid amides, such as oleamide, erucic acid amide, stearamide, ethylenebis(stearamide), etc.; fatty acid salts (e.g., metal salts), such as calcium stearate, zinc stearate, magnesium stearate, iron stearate, manganese stearate, nickel stearate, cobalt stearate, etc.; fatty acid esters, such as fatty acid esters of aliphatic alcohols (e.g., 2-ethylhexanol, monoethylene glycol, isotridecanol, propylene glycol, pentaerythritol, etc.), fatty acid esters of glycerol (e.g., castor oil, sesame oil, etc.), fatty acid esters of polyphenols, sugar fatty acid esters, etc.; and any mixtures thereof. Hydrocarbon waxes can also be used, including paraffin wax, polyolefin wax and oxidized polyolefin wax, and microcrystalline wax. Particularly suitable are acids, salts or amides of stearic acid, such as stearic acid, calcium stearate, pentaerythritol tetrastearate or N,N'-ethylene-bis-stearamide. When used, plasticizers generally comprise from about 0.05 wt. % to about 1.5 wt. %, and in some embodiments from about 0.1 wt. % to about 0.5 wt. % of the polymer matrix.
[0027] B. Therapeutic agents
[0028] One or more therapeutic agents are dispersed in the core polymer matrix, and the one or more therapeutic agents can prevent and / or treat the patient's eye disorders. The therapeutic agent can have preventive activity, therapeutic activity and / or cosmetic activity in the whole body or locally. The therapeutic agent can have preventive activity, therapeutic activity and / or cosmetic activity in the whole body or locally. In some embodiments, the therapeutic agent can be a macromolecular compound with a relatively large molecular weight, such as about 1 kilodalton (kDa) or larger, about 2kDa to about 1000kDa in some embodiments, about 20kDa to about 950kDa in some embodiments, about 50kDa to about 750kDa in some embodiments, and in some embodiments, about 100kDa to about 500kDa, or any range therebetween. The macromolecular compound can, for example, include proteins, peptides, enzymes, antibodies, interferons, interleukins, blood factors, vaccines, nucleotides, lipids or their analogs, derivatives or combinations thereof. Alternatively, small molecule therapeutic agents may be employed, such as those having a molecular weight of less than about 1,000 Da, in some embodiments about 900 Da or less, in some embodiments about 10 to about 800 Da, in some embodiments about 20 to about 700 Da, or any range therebetween.
[0029] The therapeutic agent may be naturally occurring or artificially produced by any method known in the art. Specific examples of suitable therapeutic agents may include, for example, proteins, peptides, enzymes, antibodies, interferons, interleukins, blood factors, vaccines, nucleotides, lipids, small molecule drug compounds, and the like, and analogs, derivatives, and combinations thereof. For example, therapeutic agents may include nonsteroidal anti-inflammatory drugs (e.g., salicylates, indomethacin, ibuprofen, diclofenac, flurbiprofen, piroxicam); antiallergic drugs (e.g., sodium cromolyn, antazoline, methapyriline, chlorpheniramine, cetrizine, pyrilamine, prophenpyridamine); antiproliferative agents (e.g., 1,3-cis retinoic acid); decongestants (e.g., phenylephrine, naphazoline, tetrahydrazoline); miotic and anticholinesterase agents (e.g., pilocarpine); pilocarpine, salicylates, carbachol, acetylcholine chloride, physostigmine, eserine, diisopropyl fluorophosphate, diethiophosphocholine iodine, demecarium bromide); antineoplastic agents (e.g., carmustine, cisplatin, fluorouracil); immunological drugs (e.g., vaccines and immunostimulants); hormone preparations (e.g., estrogens, estradiol, progestins, progesterone, insulin, calcitonin, parathyroid hormone, peptides and vasopressin hypothalamic releasing factor); immunosuppressants, growth hormone antagonists, growth factors (e.g., epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, transforming growth factor-β, growth hormone, fibronectin); angiogenesis inhibitors (e.g., angiostatin, anecortave acetate, acetate), thrombospondin); interferons (e.g., interferon α-2b, PEG interferon α-2a, interferon α-2b + ribavirin, pegylated interferon-2a, interferon β-1a, interferon β); interleukins (e.g., interleukin-2); vaccines (e.g., whole virus particles, recombinant proteins, subunit proteins, gp41, gp120, gp140, DNA vaccines, plasmids, bacterial vaccines, polysaccharides, extracellular capsule polysaccharides); dopamine agonists; radiotherapeutic agents; peptides; proteins; enzymes; extracellular matrix components; ACE inhibitors; free radical scavengers; chelating agents; antioxidants; anti-polymerase agents; photodynamic therapy agents; gene therapy agents; and other therapeutic agents, such as prostaglandins, anti-prostaglandins, prostaglandin precursors, etc.
[0030] If desired, in some embodiments, the implantable device may be suitable for delivering antibodies ("Ab") as therapeutic agents. The term "antibody" includes, for example, naturally occurring and non-naturally occurring Abs, monoclonal Abs and polyclonal Abs, chimeric Abs and humanized Abs; human Abs or non-human Abs, fully synthetic Abs, single-chain Abs, etc. Non-human Abs can be humanized by recombinant methods to reduce their immunogenicity in humans. The term "antibody" also includes antigen-binding fragments or antigen-binding portions of any of the above-mentioned immunoglobulins, as well as monovalent and bivalent fragments or portions, and single-chain Abs. Particularly suitable antibodies may include monoclonal antibodies ("MAbs"), multispecific antibodies (e.g., bispecific) antibodies, or combinations thereof. The term "monoclonal antibody" generally refers to a non-naturally occurring preparation of an Ab molecule composed of a single molecule, that is, an Ab molecule with substantially the same primary sequence, which exhibits a single binding specificity and affinity for a specific epitope. On the other hand, multispecific antibodies can bind to different antigens (e.g., two antigens) simultaneously. Such antibodies are generally produced by hybridomas, recombination, transgenics, or other techniques known to those skilled in the art. "Human antibody" refers to an Ab having a variable region in which the framework region and the CDR region are derived from human germline immunoglobulin sequences. In addition, if the Ab contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. Human Ab may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutations in vivo). However, as used herein, the term "human antibody" is not intended to include Abs in which the CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been transplanted to human skeleton sequences.
[0031] If necessary, in some embodiments, the implantable device can be suitable for delivering steroidal agents as therapeutic agents. Steroidal agents can include one or more corticosteroids, such as glucocorticoids. Glucocorticoids are defined as a subclass of corticosteroids. Glucocorticoids, sometimes also referred to as glucocorticoids, are a class of steroid hormones that bind to glucocorticoid receptors and are part of the immune system's feedback mechanism, which can reduce immune activity (e.g., inflammation). In medicine, they are used to treat diseases caused by an overactive immune system, such as allergies, asthma, autoimmune diseases, and sepsis. They also interfere with some abnormal mechanisms in cancer cells, so they are also used to treat cancer. After binding, the glucocorticoid receptor, i.e., the activated glucocorticoid receptor complex, upregulates the expression of anti-inflammatory proteins in the nucleus through a process called transactivation, and inhibits the expression of pro-inflammatory proteins in the cytoplasm by weakening the effect on gene induction (through NF-κB, AP1, Jun-Jun-homodimers, etc.).
[0032] Suitable examples of glucocorticoids can include hydrocortisone, cortisone acetate, cortisone / cortisol, fluocortolone, fluocinolone, fluorometholone, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, paramethasone, etc., and derivatives and combinations thereof. Dexamethasone and derivatives thereof are particularly suitable. The polymorphs, isomers, hydrates, solvates or derivatives thereof of glucocorticoids are all intended to be encompassed within the scope of the present disclosure, and should be understood to fall within the term "glucocorticoids".
[0033] If necessary, in some embodiments, the implantable device can be suitable for delivering nucleic acids as therapeutic agents. The therapeutic agent may include one or more nucleic acids. As used herein, the term "nucleic acid" generally refers to a compound comprising a core base and an acidic portion, for example, a nucleoside, a nucleotide, a polynucleotide, or a combination thereof. "Nucleoside" generally refers to a compound containing a sugar molecule (e.g., pentose or ribose) or a derivative thereof and an organic base (e.g., purine or pyrimidine) or a derivative thereof (also referred to herein as "core base"). "Nucleotide" generally refers to a nucleoside comprising a phosphate group. Modified nucleotides can be synthesized by any useful method (e.g., chemical, enzymatic or recombinant) to include one or more modified or non-natural nucleosides. A polynucleotide may include a region of one or more connected nucleosides. This region may have a variable backbone linkage. The linkage may be a standard phosphodiester bond, in which case the polynucleotide will include multiple nucleotide regions. For example, a polynucleotide may contain three or more nucleotides that are linear molecules, wherein adjacent nucleotides are connected to each other by phosphodiester bonds. The term "nucleic acid" also encompasses RNA and single-stranded and / or double-stranded DNA. More specifically, the nucleic acid can be or can include, for example, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA, including LNA with β-D-ribose configuration, α-LNA with α-L-ribose configuration (diastereomer of LNA), 2'-amino-LNA with 2'-amino functionalization, and 2'-amino-c-LNA with 2'-amino functionalization), ethylene nucleic acid (ENA), cyclohexenyl nucleic acid (CeNA) or chimeras or combinations thereof.
[0034] Nucleic acid can be naturally occurring, for example, in the context of a genome, transcript, mRNA, tRNA, rRNA, siRNA, snRNA, plasmid, cosmid, chromosome, chromatid or other naturally occurring nucleic acid molecules. On the other hand, nucleic acid molecules can be non-naturally occurring molecules, for example, recombinant DNA or RNA, artificial chromosomes, engineered genomes or fragments thereof, or synthetic DNA, RNA, DNA / RNA hybrids, or include non-naturally occurring nucleotides or nucleosides. Nucleic acid can be purified from natural sources, produced using a recombinant expression system, and optionally purified, chemically synthesized, etc. Nucleic acid can also include nucleoside analogs (e.g., analogs with chemically modified bases or sugars) and backbone modifications. In some embodiments, the nucleic acid is or contains natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrole-pyrimidine, 3-methyladenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methyl cytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); inserted bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioate and 5'-N-phosphoramidite bonds).
[0035] Modified nucleotide base pairing can be employed, and includes not only standard adenosine-thymine, adenosine-uracil or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and / or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors allows hydrogen bonding between non-standard bases and standard bases or between two complementary non-standard bases. An example of such non-standard base pairing is base pairing between modified nucleotides inosine and adenine, cytosine or uracil. Any combination of bases / sugars or linkers can be incorporated into the polynucleotides of the present disclosure.
[0036] In certain embodiments, the nucleic acid can be a polynucleotide (e.g., an RNA polynucleotide, such as an mRNA polynucleotide) in which one or more nucleobases have been modified for therapeutic purposes. In fact, in certain embodiments, a polynucleotide (e.g., an RNA polynucleotide, such as an mRNA polynucleotide) can be used that includes at least two (e.g., 2, 3, 4 or more) modified nucleobases. For example, suitable modified nucleobases in the polynucleotide can be: modified cytosine, such as 5-methylcytosine, 5-methyl-cytidine (m5C), N4-acetyl-cytidine (ac4C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine, etc.; modified uridine, such as 5-cyanouridine, 4'-thiouridine, uridine, pseudouridine (ψ), N1-methyl pseudouridine (m1ψ), N1-ethyl pseudouridine, 2-thiouridine (s2U), 4'-thiouridine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine (mo5U), 5-methoxyuridine, 2′-O-methyluridine, etc.; modified guanosine, such as α-thio-guanosine, inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methyl wyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (p reQO), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, etc.; modified adenine, such as α-thio-adenosine, 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), 2,6-diaminopurine, etc.; and combinations thereof. In some embodiments, a polynucleotide (e.g., an RNA polynucleotide, such as an mRNA polynucleotide) includes at least two (e.g., 2, 3, 4 or more) of the above-mentioned modified nucleobases.
[0037] In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) can be uniformly modified (e.g., fully modified, modified throughout the sequence) for a particular modification. For example, a polynucleotide can be uniformly modified with 5-methyl-cytidine (m5C), meaning that all cytosine residues in the mRNA sequence are replaced with 5-methyl-cytidine (m5C). Similarly, a polynucleotide can be uniformly modified with any type of nucleoside residue present in the sequence by replacing it with a modified residue (such as any of those modified residues described above).
[0038] In some embodiments, polynucleotides serve as messenger RNA (mRNA). "Messenger RNA" (mRNA) generally refers to any polynucleotide that encodes (at least one) polypeptide (naturally occurring, non-naturally occurring or modified amino acid polymer) and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ or in vitro. The basic composition of mRNA molecules generally includes at least one coding region, 5' untranslated region (UTR), 3'UTR, 5' cap and poly-A tail. Polynucleotides can act as mRNA, but the difference between polynucleotides and wild-type mRNA is that their functional and / or structural design features are used to overcome the existing problems of effective polypeptide expression using nucleic acid-based therapeutic agents. mRNA can contain at least one (one or more) ribonucleic acid (RNA) polynucleotides having an open reading frame encoding at least one polypeptide of interest. In some embodiments, the RNA polynucleotide of the mRNA encodes 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 polypeptides. In some embodiments, the RNA polynucleotides of the mRNA encode at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 polypeptides. In some embodiments, the RNA polynucleotides of the mRNA encode at least 100 or at least 200 polypeptides.
[0039] In some embodiments, nucleic acid is therapeutic mRNA. As used herein, the term "therapeutic mRNA" refers to mRNA encoding therapeutic proteins. Therapeutic proteins mediate multiple effects in host cells or objects to treat diseases or improve the signs and symptoms of diseases. For example, therapeutic proteins can replace defective or abnormal proteins, enhance the function of endogenous proteins, provide new functions for cells (for example, inhibit or activate endogenous cell activity, or as a delivery agent for another therapeutic compound (for example, antibody-drug conjugate). Therapeutic mRNA can be used to treat various diseases and disorders, such as bacterial infections, viral infections, parasitic infections, cell proliferation disorders, hereditary disorders and autoimmune diseases. mRNA can be designed to encode a polypeptide of interest selected from any of the following target categories, and target categories include but are not limited to: biologics, antibodies, vaccines, therapeutic proteins or peptides, cell penetrating peptides, secretory proteins, plasma membrane proteins, cytoplasmic or cytoskeletal proteins, intracellular membrane-bound proteins, nucleoproteins, proteins related to human diseases, targeting groups or proteins encoded by the human genome that have not yet determined therapeutic indications but are useful in the field of research and discovery.
[0040] Particularly suitable therapeutic mRNAs are those that include at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide, wherein the RNA polynucleotide of the RNA includes at least one chemical modification. The chemical modification can be, for example, pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine.
[0041] Although not necessary, the specific properties of nucleic acid can also be selected to help improve its ability to be dispersed in a polymer matrix and delivered to a patient without significant degradation. For example, it may be necessary to co-deliver conventional RNA (e.g., mRNA) and self-amplification RNA. For example, conventional mRNA generally includes an open reading frame of a target antigen, which is flanked by an untranslated region and has a terminal poly A (poly (A)) tail. After transfection, they drive transient antigen expression. On the other hand, self-amplification mRNA can guide its self-replication by synthesizing RNA-dependent RNA polymerase complexes, produce multiple copies of mRNA encoding antigens, and express high levels of heterologous genes when they are introduced into the cytoplasm of host cells. Circular RNA (circRNA) can also be used, which is a single-stranded RNA connected end to end. Target RNA can be, for example, cyclized by the back splicing of non-mammalian exogenous introns or the bridging connection of 5' and 3' ends of linear RNA. Examples of suitable circRNA are described in, for example, U.S. Patent Publication No. 2019 / 0345503, which is incorporated herein by reference. Antisense RNAs may also be employed, which typically have bases carried on backbone subunits consisting of morpholino backbone groups, and wherein the backbone groups are linked by intersubunit bonds (charged and uncharged), which allow the bases in the compound to hybridize to a target sequence in the RNA by Watson-Crick base pairing, thereby forming an RNA:oligonucleotide heteroduplex nucleic acid molecule within the target sequence. Morpholino oligonucleotides, including antisense oligonucleotides, having uncharged backbone bonds are described in detail, for example, in U.S. Pat. Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,185,444, 5,521,063, and 5,506,337, which are incorporated herein by reference. Other exemplary antisense oligonucleotides are described in US Pat. Nos. 9,464,292, 10,131,910, 10,144,762, and 10,913,947, which are incorporated herein by reference.
[0042] In some cases, nucleic acid can be an aptamer, such as an RNA aptamer. RNA aptamers can be any suitable RNA molecules, which can be used as independent molecules by themselves, or can be used as a part of a larger RNA molecule (such as RNA interference molecules) with multiple functions. For example, RNA aptamers can be located in the exposed area of shRNA molecules (for example, the loop area of shRNA molecules) to allow shRNA or miRNA molecules to bind to surface receptors on target cells. After RNA aptamers are internalized, they can be processed by the RNA interference pathway of target cells. The nucleic acid forming nucleic acid aptamers can include naturally occurring nucleosides, modified nucleosides, naturally occurring nucleosides with hydrocarbon joints (for example, alkylene) and / or polyether joints (for example, PEG joints) inserted between one or more nucleosides, modified nucleosides with hydrocarbons or PEG joints inserted between one or more nucleosides, or combinations thereof. In some embodiments, the nucleotides of nucleic acid aptamers or modified nucleotides can be replaced with hydrocarbon joints or polyether joints. Suitable aptamers can be described in, for example, U.S. Patent No. 9,464,293, which is incorporated herein by reference.
[0043] The nucleic acid of protein fusion is also applicable to the present invention.For example, protein (for example, antibody) can be covalently linked to RNA (for example, mRNA).This RNA-protein fusion can be synthesized by in vitro or in situ translation containing the mRNA pool of the peptide acceptor connected to its 3' end.In one embodiment, after the open reading frame of the read-through information, the ribosome pauses when arriving at the pause site of the design, and the acceptor part occupies the ribosome A site and accepts the nascent peptide chain of the peptidyl-tRNA from the P site to produce RNA-protein fusion.The covalent connection between protein and RNA (in the form of amide bond between mRNA 3' end and the protein C-terminal end encoded therein) allows the genetic information in the protein to be recovered and amplified (for example, by PCR), and then selected by reverse transcription of RNA.Once fusion is produced, selection or enrichment is carried out based on the property of mRNA-protein fusion, or, reverse transcription can be carried out using mRNA template, and mRNA template is connected to protein to avoid the influence of single-stranded RNA on selection.For example, the example of this protein fusion nucleic acid is described in U.S. Patent number 6,518,018, which is incorporated herein by reference. Ribozymes (eg, DNA enzymes and / or RNA enzymes) conjugated to nucleic acids having sequences that catalyze the cleavage of RNA can also be used, for example as described in US Pat. No. 10,155,946, which is incorporated herein by reference.
[0044] In addition to the single-stranded nucleic acid as described above, various specific types of double-stranded nucleic acids can also be used to help improve stability. Circular DNA (cDNA) and plasmid nucleic acid (e.g., pDNA) are closed circular forms of DNA, which can be used in certain embodiments. Examples of such nucleic acids are described in, for example, WO 2004 / 060277, which is incorporated herein by reference. Long double-stranded DNA can also be used. For example, a skeleton-supported DNA origami can be used, wherein the skeleton is annealed in the presence of a shorter oligonucleotide ("staples") containing a segment or region complementary to the skeleton, and the long single-stranded DNA is folded into a certain shape. Examples of this structure are described in, for example, U.S. Patent Publication Nos. 2019 / 0142882 and 2018 / 0171386, which are incorporated herein by reference.
[0045] If desired, in some embodiments, the implantable device can be suitable for delivering a tyrosine kinase inhibitor as a therapeutic agent. As used herein, the term "tyrosine kinase inhibitor" generally refers to a molecule, mimetic, or derivative that can reduce, block, eliminate, and / or interfere with one or more biological activities (including tyrosine kinase activity). Tyrosine kinases are enzymes responsible for activating many proteins through signal transduction cascades. For example, tyrosine kinase inhibitors ("TKIs") can bind to the adenosine triphosphate (ATP) binding site of VEGF, thereby blocking intracellular signal transduction.
[0046] In some embodiments, the tyrosine kinase inhibitor may include, but is not limited to, an epidermal growth factor (EGF) pathway inhibitor, a platelet-derived growth factor (PDGF) pathway inhibitor, a RAF-1 inhibitor, or a combination thereof. The tyrosine kinase inhibitor may include, but is not limited to, axitinib, bosutinib, cabozantinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, ponatinib, ruxolitinib, sorafenib, sunitinib, vatalanib, vemurafenib, or a combination thereof. For example, axitinib (molecular weight 386.5Da) is a tyrosine kinase inhibitor that inhibits VEGF activity (such as new blood vessel formation). Therefore, axitinib and other TKIs can be used to treat neovascular (wet) age-related macular degeneration (AMD), treat visual impairment caused by diabetic macular edema (DME), treat visual impairment caused by macular edema secondary to retinal vein occlusion (branch RVO or central RVO), treat visual impairment caused by choroidal neovascularization (CNV) secondary to pathological myopia, or treat other retinal diseases. For example, cabozantinib (molecular weight 501.5Da) is a TKI that downregulates the activation of tyrosine kinases (such as VEGF receptors) involved in tumor angiogenesis.
[0047] The therapeutic agent can generally be stable at sufficiently high temperatures so that it can be incorporated into the polymer matrix without significant degradation (e.g., melting) during the manufacture or use of the device at or near the melting temperature of the ethylene-vinyl acetate polymer used in the core. For example, the therapeutic agent can be stable at a temperature of about 20°C to about 100°C, in some embodiments about 25°C to about 80°C, in some embodiments about 30°C to about 70°C, in some embodiments about 35°C to about 65°C, and in some embodiments about 40°C to about 60°C. The therapeutic agent can be inherently stable at such temperatures, or it can also be encapsulated or otherwise protected by a carrier component that is stable at such temperatures, such as a carrier component comprising a peptide, protein, carbohydrate (e.g., sugar), polymer, lipid, etc. In a specific embodiment, for example, the carrier component can include a lipid, which generally refers to a small molecule having hydrophobic or amphiphilic properties, such as fats, waxes, sterol-containing metabolites, vitamins, fatty acids, glycerolipids, glycerophospholipids, sphingomyelins, glycolipids, polyketides, and isopentanol lipids. Examples of such lipids can include, for example: phospholipids, such as alkylphosphocholine and / or fatty acid-modified phosphocholine (e.g., 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)); cationic lipids, such as 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)-butyryl)oxy)heptadecanedioate (L319); auxiliary lipids (e.g., fatty acids); structural lipids (e.g., sterols); polyethylene glycol (PEG) conjugated lipids, etc., and combinations of any of the above. Regardless, at least one of the compounds (e.g., lipids) employed in the carrier component can be selected to have a melting temperature similar to or higher than the melting temperature of the ethylene-vinyl acetate copolymer in the core. In fact, in certain embodiments, multiple compounds or even all of the compounds within the carrier component can be selected to have a melting temperature similar to or higher than the melting temperature of the ethylene-vinyl acetate copolymer in the polymer matrix. In this way, the encapsulated steroidal agent can remain stable at or near the melt processing temperature of the ethylene-vinyl acetate copolymer used in the core (generally higher than the melting temperature of such copolymer).For example, the ratio of the melting temperature (°C) of the ethylene-vinyl acetate copolymer in the core to the melting temperature (°C) of the compound (e.g., lipid) in the carrier component can be about 2°C / °C or less, in some embodiments about 1.8°C / °C or less, in some embodiments about 0.1°C / °C to about 1.6°C / °C, in some embodiments about 0.2°C / °C to about 1.5°C / °C, and in some embodiments about 0.4°C / °C to about 1.2°C / °C. For example, as determined according to ASTM D3418-15, the ethylene-vinyl acetate copolymer and the resulting polymer matrix can have a melting temperature of, for example, about 20°C to about 100°C, in some embodiments about 25°C to about 80°C, in some embodiments about 30°C to about 70°C, in some embodiments about 35°C to about 65°C, and in some embodiments about 40°C to about 60°C. The compounds (e.g., lipids) within the carrier component may similarly have a melting temperature of about 25°C to about 105°C, in some embodiments about 30°C to about 85°C, in some embodiments about 35°C to about 75°C, in some embodiments about 40°C to about 70°C, and in some embodiments about 45°C to about 65°C.
[0048] C. excipient
[0049] The core may also optionally contain one or more excipients, such as cell permeability enhancers, radiocontrast agents, hydrophilic compounds, fillers, surfactants, crosslinking agents, flow aids, colorants (e.g., chlorophyll, methylene blue, etc.), antioxidants, stabilizers, lubricants, other types of antimicrobial agents, preservatives, etc., to enhance performance and processability. Optional excipients typically account for about 0.01wt.% to about 20wt.% of the core, and about 0.05wt.% to about 15wt.% in some embodiments, and about 0.1wt.% to about 10wt.% in some embodiments. In one embodiment, for example, a radiocontrast agent can be used to help ensure that the device can be detected under X-ray-based imaging techniques (e.g., computed tomography, projection radiography, fluoroscopy, etc.). Examples of such agents include, for example, barium-based compounds, iodine-based compounds, zirconium-based compounds (e.g., zirconium dioxide), etc. A specific example of such an agent is barium sulfate. Other known antimicrobial agents and / or preservatives may also be used to help prevent surface growth and attachment of bacteria, such as metal compounds (eg, silver, copper, or zinc), metal salts, quaternary ammonium compounds, and the like.
[0050] To help further control the release rate from the implantable device, a hydrophilic compound that is soluble and / or swellable in water can also be incorporated into the core. When used, the weight ratio of the ethylene-vinyl acetate copolymer to the hydrophilic compound in the core can be about 0.25 to about 200, in some embodiments about 0.4 to about 80, in some embodiments about 0.8 to about 20, in some embodiments about 1 to about 16, and in some embodiments about 1.2 to about 10. Such a hydrophilic compound can, for example, account for about 1 wt.% to about 60 wt.% of the core, in some embodiments about 2 wt.% to about 50 wt.%, and in some embodiments about 5 wt.% to about 40 wt.%, while ethylene-vinyl acetate copolymers typically account for about 40 wt.% to about 99 wt.% of the core, in some embodiments about 50 wt.% to about 98 wt.%, and in some embodiments about 60 wt.% to about 95 wt.%. Suitable hydrophilic compounds can include, for example, polymers, non-polymeric materials (e.g., glycerol, sugars, sugar alcohols, salts, etc.), etc. Examples of suitable hydrophilic polymers include, for example, sodium alginate, potassium alginate and calcium alginate, carboxymethyl cellulose, agar, gelatin, polyvinyl alcohol, polyalkylene glycols (such as polyethylene glycol), collagen, pectin, chitin, chitosan, poly-1-caprolactone, polyvinyl pyrrolidone, poly (vinyl pyrrolidone-co-vinyl acetate), polysaccharides, hydrophilic polyurethanes, polyhydroxyacrylates, dextran, xanthan gum, hydroxypropyl cellulose, methyl cellulose, proteins, ethylene-vinyl alcohol copolymers, water-soluble polysilanes and water-soluble silicones, water-soluble polyurethanes, and the like, and combinations thereof. Particularly suitable hydrophilic polymers are polyalkylene glycols, such as those having a molecular weight of about 100 g / mol to 500,000 g / mol, in some embodiments about 500 g / mol to 200,000 g / mol, and in some embodiments about 1000 g / mol to 100,000 g / mol. Specific examples of such polyalkylene glycol include, for example, polyethylene glycol, polypropylene glycol, polytetramethylene glycol, polyepichlorohydrin and the like.
[0051] One or more nonionic, anionic and / or amphoteric surfactants can also be used to help form a uniform dispersion. When used, this surfactant usually accounts for about 0.05wt.% to about 8wt.% of the film layer, and in some embodiments about 0.1wt.% to about 6wt.%, and in some embodiments about 0.5wt.% to about 3wt.%. It is particularly suitable to generally have a hydrophobic group (e.g., a long-chain alkyl group or an alkylated aryl group) and a hydrophilic chain (e.g., a chain containing an ethoxylated portion and / or a propoxylated portion). Some suitable nonionic surfactants that can be used include, but are not limited to, ethoxylated alkylphenols, ethoxylated fatty alcohols and propoxylated fatty alcohols, polyethylene glycol ethers of methyl glucose, polyethylene glycol ethers of sorbitol, ethylene oxide-propylene oxide block copolymers, fats (C8-C 18 ) ethoxylated esters of acids, condensation products of ethylene oxide with long-chain amines or long-chain amides, condensation products of ethylene oxide with alcohols, fatty acid esters, monoglycerides or diglycerides of long-chain alcohols, and mixtures thereof. Particularly suitable nonionic surfactants may include ethylene oxide condensates of fatty alcohols, polyoxyethylene ethers of fatty acids, polyoxyethylene sorbitan fatty acid esters, and sorbitan fatty acid esters, and the like. The fat component used to form such an emulsifier may be saturated or unsaturated, substituted or unsubstituted, and may contain 6 to 22 carbon atoms, in some embodiments 8 to 18 carbon atoms, and in some embodiments 12 to 14 carbon atoms. Sorbitol fatty acid esters (e.g., monoesters, diesters, triesters, etc.) that have been modified with polyoxyethylene are a particularly useful class of nonionic surfactants. These materials are typically prepared by adding ethylene oxide to 1,4-sorbitan esters. The addition of polyoxyethylene converts the lipophilic sorbitan ester surfactant into a hydrophilic surfactant that is generally soluble or dispersible in water. Such materials may be referred to under the name (For example, 80 or polyoxyethylene (20) sorbitan monooleate) is commercially available.
[0052] In some cases, the hydrophilic compound can be in the form of water-soluble particles distributed in the core polymer matrix. The particle size of the water-soluble particles can be controlled to help achieve the desired delivery rate. More specifically, for example, as measured using a laser scattering particle size distribution analyzer (e.g., LA-960 from Horiba), the median diameter (D50) of the particles can be about 100 microns or less, about 80 microns or less in some embodiments, about 60 microns or less in some embodiments, and about 1 micron to about 40 microns in some embodiments. The particles can also have a narrow size distribution so that 90% or more of the particles (D90) by volume have a diameter within the above range. In addition to controlling the particle size, the material for forming the water-soluble particles can also be selected to achieve the desired release curve. For example, the water-soluble particles can include non-polymeric hydroxyl-functionalized compounds. The term "hydroxy-functionalized" generally means that the compound includes at least one hydroxyl group, and in some cases includes multiple hydroxyl groups, such as 2 or more, 3 or more in some embodiments, 4 to 20 in some embodiments, and 5 to 16 hydroxyl groups in some embodiments. The term "non-polymeric" similarly generally means that the compound does not contain a significant number of repeating units, for example, no more than 10 repeating units, no more than 5 repeating units in some embodiments, no more than 3 repeating units in some embodiments, and no more than 2 repeating units in some embodiments. In some cases, this compound does not have any repeating units. Therefore, this non-polymeric compound has a relatively low molecular weight, for example, about 1 g / mol to about 650 g / mol, about 5 g / mol to about 600 g / mol in some embodiments, about 10 g / mol to about 550 g / mol in some embodiments, about 50 g / mol to about 500 g / mol in some embodiments, about 80 g / mol to about 450 g / mol in some embodiments, and about 100 g / mol to 400 g / mol in some embodiments. Particularly suitable non-polymeric, hydroxy-functionalized compounds that can be used in the present invention include, for example, sugars and their derivatives, such as monosaccharides (e.g., dextrose, fructose, galactose, ribose, deoxyribose, etc.); disaccharides (e.g., sucrose, lactose, maltose, etc.); sugar alcohols (e.g., xylitol, sorbitol, mannitol, maltitol, erythritol, dulcitol, isomalt, inositol, lactitol, etc.); etc., and combinations thereof.
[0053] Regardless of the specific components used, the core can be formed by various known techniques, such as by hot melt extrusion, injection molding, solvent casting, dip coating, spray coating, micro extrusion, coagulation, etc. In one embodiment, hot melt extrusion technology can be used. Hot melt extrusion is generally a solvent-free process, in which the components of the core (e.g., ethylene-vinyl acetate copolymer, therapeutic agent, optionally excipient, etc.) can be melt blended and optionally molded in a continuous manufacturing process to ensure consistent output quality under high throughput rates. This technology is particularly suitable for ethylene-vinyl acetate copolymers because they generally show a relatively high degree of long chain branching and a wide molecular weight distribution. During the extrusion process, this combination of characteristics can lead to shear thinning of the copolymer, which helps hot melt extrusion. In addition, the polar vinyl acetate comonomer unit can act as an "internal" plasticizer by inhibiting the crystallization of the polyethylene segment. This may result in a lower melting point of the copolymer, thereby further enhancing its ability to be processed with the therapeutic agent.
[0054] In the hot melt extrusion process, melt blending is usually carried out at a temperature similar to or even lower than the melting temperature of the therapeutic agent or the carrier component (e.g., lipid) for the therapeutic agent. Melt blending may also be carried out at a temperature similar to or slightly higher than the melting temperature of ethylene-vinyl acetate copolymer. The ratio of the melt blending temperature to the melting temperature of the carrier component for the therapeutic agent and / or the therapeutic agent may be, for example, about 2 or less, about 1.8 or less in some embodiments, about 0.1 to about 1.6 in some embodiments, about 0.2 to about 1.5 in some embodiments, and about 0.4 to about 1.2 in some embodiments. The melt blending temperature may be, for example, about 30°C to about 100°C, about 40°C to about 80°C in some embodiments, and about 50°C to about 70°C in some embodiments. Any of various melt blending techniques can generally be used. For example, the component can be supplied alone or in combination to an extruder, and the extruder includes at least one screw rotatably mounted and contained in a barrel (e.g., a cylindrical barrel). The extruder may be a single screw or a twin screw extruder. For example, one embodiment of a single screw extruder may include a housing or barrel and a screw that is rotatably driven at one end by a suitable driver (typically including a motor and a gearbox). If desired, a twin screw extruder comprising two independent screws may be used. The configuration of the screw is not particularly critical, and as known in the art, the screw may include threads and channels of any number and / or orientation. For example, the screw typically includes threads that form a generally spiral channel extending radially around the center of the screw. A feed section and a melting section may be defined along the length of the screw. The feed section is the input portion of the barrel, where ethylene-vinyl acetate copolymer and / or therapeutic agent are added. The melting section is a phase change section where the copolymer is transformed from a solid state to a liquid state. Although there is no precise definition of these sections when manufacturing the extruder, a person of ordinary skill in the art can reliably determine the feed section and the melting section where a phase change from solid to liquid occurs. Although not necessarily required, the extruder may also have a mixing section adjacent to the output end of the barrel and located downstream of the melting section. If desired, one or more distribution and / or dispersion mixing elements may be used in the mixing section and / or melting section of the extruder. Suitable distributive mixers for single screw extruders may include, for example, Saxon, Dulmage, Cavity Transfer mixers, etc. Similarly, suitable dispersive mixers may include Blister rings, Leroy / Maddock, CRD mixers, etc. As is well known in the art, mixing may be further improved by using pins in the barrel that fold and redirect the polymer melt, such as those used in Buss Kneader extruders, Cavity Transfer mixers, and Vortex Intermeshing Pin mixers.
[0055] If desired, the ratio of the length ("L") to the diameter ("D") of the screw can be selected to achieve the best balance between the throughput and blending of the components. The L / D value can be, for example, from about 10 to about 50, from about 15 to about 45 in some embodiments, and from about 20 to about 40 in some embodiments. The length of the screw can be, for example, from about 0.1 meter to about 5 meters, from about 0.4 meter to about 4 meters in some embodiments, and from about 0.5 meter to about 2 meters in some embodiments. The diameter of the screw can also be from about 5 millimeters to about 150 millimeters, from about 10 millimeters to about 120 millimeters in some embodiments, and from about 20 millimeters to about 80 millimeters in some embodiments. In addition to the length and diameter, other aspects of the extruder can also be selected to help achieve the desired degree of blending. For example, the speed of the screw can be selected to achieve the desired residence time, shear rate, melt processing temperature, etc. For example, the screw speed can be from about 10 revolutions per minute ("rpm") to about 800rpm, from about 20rpm to about 500rpm in some embodiments, and from about 30rpm to about 400rpm in some embodiments. The apparent shear rate during melt blending may also be about 100 sec -1 to about 10,000 seconds -1 , in some embodiments about 500 seconds -1 to about 5000 seconds -1 , and in some embodiments about 800 seconds -1 to about 1200 seconds -1 The apparent shear rate is equal to 4Q / πR 3 , where Q is the volume flow rate of the polymer melt (“m 3 / s”), and R is the radius (“m”) of the capillary (e.g., extruder die) through which the molten polymer flows.
[0056] Once melt blended together, the resulting polymer composition can be extruded through an orifice (e.g., a mold) and formed into pellets, sheets, fibers, filaments, etc., which can then be formed into a core using various known molding techniques, such as injection molding, compression molding, nano molding, secondary molding, blow molding, three-dimensional printing, etc. Injection molding can, for example, occur in two main stages, namely an injection stage and a holding stage. During the injection stage, the mold cavity is filled with a molten polymer composition. The holding stage begins after the injection stage is completed, at which stage, the holding pressure is controlled to fill the additional material into the cavity and compensate for the volume shrinkage that occurs during cooling. After the injection is completed, it can be subsequently cooled. Once cooling is completed, when the mold is opened and the part is ejected (e.g., with the help of an ejector pin in the mold), the molding cycle is completed. The present invention can generally use any suitable injection molding equipment. In one embodiment, an injection molding device including a first mold base and a second mold base can be used, and the first mold base and the second mold base together define a mold cavity having the shape of a core. The molding device includes a resin flow path, which extends from the outer surface of the first half mold to the mold cavity through a runner. Various techniques can be used to supply the polymer composition to the resin flow path. For example, the composition can be supplied (e.g., in the form of pellets) to a feed hopper that is connected to an extruder barrel comprising a rotating screw (not shown). As the screw rotates, the pellets move forward and are subjected to pressure and friction, which generate heat to melt the pellets. A cooling mechanism can also be provided to solidify the resin in the mold cavity into the shape of a desired core (e.g., a disc, a rod, etc.). For example, the mold base can include one or more cooling lines, and a cooling medium flows through the cooling lines so that the mold base surface has a desired mold temperature to solidify the molten material. The mold temperature (e.g., the temperature of the mold surface) can be from about 50°C to about 120°C, from about 60°C to about 110°C in some embodiments, and from about 70°C to about 90°C in some embodiments.
[0057] As mentioned above, another suitable technology for forming a core of a desired shape and size is three-dimensional printing. In this process, the polymer composition can be incorporated into a printer cartridge that is easy to use with a printer system. The printer cartridge can, for example, include a spool or other similar device that carries the polymer composition. When supplied in the form of a filament, for example, the spool can have a substantially cylindrical edge on which the filament is wound. The spool can similarly define a hole or a mandrel to allow it to be easily installed in the printer during use. The present invention can adopt any of a variety of three-dimensional printer systems. A particularly suitable printer system is an extrusion-based system, commonly referred to as a "fused deposition molding" system. For example, the polymer composition can be supplied to a build chamber of a print head including a platen and a gantry. Based on a signal provided by a computer-operated controller, the platen can be moved along a vertical z-axis. The gantry is a rail system that can be configured to move the print head in a horizontal xy plane in the build chamber based on a signal provided by the controller. The print head is supported by the gantry and is configured to print a build structure on the platen in a layer-by-layer manner based on a signal provided by the controller. For example, the print head may be a dual-head extrusion head.
[0058] Compression molding (e.g., vacuum compression molding) may also be used. In this method, the layer of the device can be formed by heating and compressing the polymer into a desired shape under vacuum. More specifically, the method may include forming the polymer composition into a precursor assembled in a chamber of a compression mold, heating the precursor, and compressing the precursor into the desired layer when the precursor is heated. The polymer composition can be formed into a precursor by various techniques, such as by dry powder mixing, extrusion, etc. The temperature during compression can be from about 50°C to about 120°C, from about 60°C to about 110°C in some embodiments, and from about 70°C to about 90°C in some embodiments. During the molding process, a vacuum source may also apply negative pressure to the precursor to help ensure that it maintains a precise shape. Examples of this compression molding technique are described in, for example, U.S. Pat. No. 10,625,444 to Treffer et al., the entire contents of which are incorporated herein by reference.
[0059] II. Film
[0060] As mentioned above, the implantable device may optionally include one or more membrane layers (e.g., a first membrane layer) disposed adjacent to the outer surface of the core. Additional membrane layers (e.g., a second membrane layer, a third membrane layer, etc.) may be stacked in layers on the core as needed. The number of membrane layers may vary according to the specific configuration of the device, the properties of the therapeutic agent, and the desired release profile. For example, in some embodiments, the device may include only one membrane layer.
[0061] When employed, the film polymer matrix comprises at least one ethylene-vinyl acetate copolymer, such as described in more detail above. The vinyl acetate content of the copolymer can be selectively controlled at about 10 wt.% to about 60 wt.%, in some embodiments about 20 wt.% to about 60 wt.%, in some embodiments about 25 wt.% to about 50 wt.%, in some embodiments about 30 wt.% to about 48 wt.%, and in some embodiments about 35 wt.% to about 45 wt.%. Conversely, the ethylene content of the copolymer can similarly be about 40 wt.% to about 90 wt.%, in some embodiments about 40 wt.% to about 80 wt.%, in some embodiments about 50 wt.% to about 75 wt.%, in some embodiments about 50 wt.% to about 80 wt.%, in some embodiments about 52 wt.% to about 70 wt.%, and in some embodiments about 55 wt.% to about 65 wt.%. The ethylene-vinyl acetate copolymer and the resulting polymer matrix may also have a melt flow index of about 0.2 g / 10 min to about 400 g / 10 min, in some embodiments 0.2 g / 10 min to about 100 g / 10 min, in some embodiments about 5 g / 10 min to about 90 g / 10 min, in some embodiments about 10 g / 10 min to about 80 g / 10 min, and in some embodiments about 30 g / 10 min to about 70 g / 10 min, as measured according to ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kg. The ethylene-vinyl acetate copolymer may also have a melting temperature of about 40° C. to about 140° C., in some embodiments about 50° C. to about 125° C., and in some embodiments about 60° C. to about 120° C., as measured according to ASTM D1505-18. The ethylene-vinyl acetate copolymer may also have a density of about 0.900 g / cm3 (g / cm 3 ) to about 1.00g / cm 3 , in some embodiments about 0.910 g / cm 3 To about 0.980g / cm 3 , and in some embodiments about 0.940 g / cm 3 To about 0.970g / cm 3 Particularly suitable examples of ethylene-vinyl acetate copolymers that may be employed include those known under the names Those obtained from Celanese (e.g., 4030AC); by name Those obtained from Dow ( 40W); and Those available from Arkema (eg, EVATANE 40-55). In some embodiments, the ethylene-vinyl acetate copolymer in the membrane polymer matrix is about 20 wt.% to about 90 wt.%, such as about 30 wt.% to about 80 wt.%, such as about 40 wt.% to about 70 wt.%.
[0062] In some cases, ethylene-vinyl acetate copolymer constitutes the whole polymer content of the film polymer matrix. However, in other cases, it may be desirable to include other polymers, such as other hydrophobic polymers. When adopted, it is generally desirable that this other polymer accounts for about 0.001wt.% to about 30wt.% of the polymer content of the polymer matrix, about 0.01wt.% to about 20wt.% in some embodiments, and about 0.1wt.% to about 10wt.% in some embodiments. In this case, ethylene-vinyl acetate copolymer can account for about 70wt.% to about 99.999wt.% of the polymer content of the polymer matrix, about 80wt.% to about 99.99wt.% in some embodiments, and about 90wt.% to about 99.9wt.% in some embodiments. The film polymer matrix generally accounts for about 50wt.% to 99wt.% of the film layer, about 55wt.% to about 98wt.% in some embodiments, about 60wt.% to about 96wt.% in some embodiments, and about 70wt.% to about 95wt.% in some embodiments.
[0063] To help further control the release rate of the self-implanted medical device, a hydrophilic compound that is soluble and / or swellable in water may also be incorporated into the film layer. When employed, the weight ratio of ethylene-vinyl acetate copolymer to hydrophilic compound in the film layer may be from about 0.25 to about 200, in some embodiments from about 0.4 to about 80, in some embodiments from about 0.8 to about 20, in some embodiments from about 1 to about 16, and in some embodiments from about 1.2 to about 10. Such a hydrophilic compound may, for example, account for about 1 wt.% to about 60 wt.% of the core, in some embodiments from about 2 wt.% to about 50 wt.%, and in some embodiments from about 5 wt.% to about 40 wt.%, while ethylene-vinyl acetate copolymer typically accounts for about 40 wt.% to about 99 wt.% of the core, in some embodiments from about 50 wt.% to about 98 wt.%, and in some embodiments from about 60 wt.% to about 95 wt.%. Suitable hydrophilic compounds may include, for example, polymers, non-polymeric materials (e.g., glycerol, sugars, sugar alcohols, salts, etc.), and the like. Examples of suitable hydrophilic polymers include, for example, sodium alginate, potassium alginate and calcium alginate, carboxymethyl cellulose, agar, gelatin, polyvinyl alcohol, polyalkylene glycols (such as polyethylene glycol), collagen, pectin, chitin, chitosan, poly-1-caprolactone, polyvinyl pyrrolidone, poly (vinyl pyrrolidone-co-vinyl acetate), polysaccharides, hydrophilic polyurethanes, polyhydroxyacrylates, dextran, xanthan gum, hydroxypropyl cellulose, methyl cellulose, proteins, ethylene-vinyl alcohol copolymers, water-soluble polysilanes and water-soluble silicones, water-soluble polyurethanes, and the like, and combinations thereof. Particularly suitable hydrophilic polymers are polyalkylene glycols, such as those having a molecular weight of about 100 g / mol to 500,000 g / mol, in some embodiments about 500 g / mol to 200,000 g / mol, and in some embodiments about 1000 g / mol to 100,000 g / mol. Specific examples of such polyalkylene glycol include, for example, polyethylene glycol, polypropylene glycol, polybutylene glycol, polyepichlorohydrin and the like.
[0064] Alternatively, the film layer may include a plurality of water-soluble particles distributed in the film polymer matrix. The particle size of the water-soluble particles is controlled to help achieve the desired delivery rate. More specifically, such as measured using a laser scattering particle size distribution analyzer (e.g., LA-960 from Horiba), the median diameter (D50) of the particles is about 100 microns or less, about 80 microns or less in some embodiments, about 60 microns or less in some embodiments, and about 1 micron to about 40 microns in some embodiments. The particles may also have a narrow size distribution so that 90% or more of the particles (D90) by volume have a diameter within the above range. In addition to controlling the particle size, the material for forming the water-soluble particles is also selected to achieve the desired release profile. More specifically, the water-soluble particles generally include non-polymeric hydroxy-functional compounds. The term "hydroxy-functional" generally refers to that the compound includes at least one hydroxyl group, and includes multiple hydroxyl groups in some cases, such as 2 or more, 3 or more in some embodiments, 4 to 20 in some embodiments, and 5 to 16 hydroxyl groups in some embodiments. The term "non-polymeric" similarly generally means that the compound does not contain a significant number of repeating units, for example, no more than 10 repeating units, no more than 5 repeating units in some embodiments, no more than 3 repeating units in some embodiments, and no more than 2 repeating units in some embodiments. In some cases, this compound does not have any repeating units. Therefore, this non-polymeric compound has a relatively low molecular weight, for example, about 1 g / mol to about 650 g / mol, about 5 g / mol to about 600 g / mol in some embodiments, about 10 g / mol to about 550 g / mol in some embodiments, about 50 g / mol to about 500 g / mol in some embodiments, about 80 g / mol to about 450 g / mol in some embodiments, and about 100 g / mol to 400 g / mol in some embodiments. Particularly suitable non-polymeric, hydroxyl-functionalized compounds that can be used in the present disclosure include, for example, sugars and their derivatives, such as monosaccharides (such as dextrose, fructose, galactose, ribose, deoxyribose, etc.); disaccharides (such as sucrose, lactose, maltose, etc.); sugar alcohols (such as xylitol, sorbitol, mannitol, maltitol, erythritol, galactitol, isomalt, inositol, lactitol, etc.); etc., and combinations thereof. If used, water-soluble particles generally account for about 1 wt.% to about 50 wt.% of the film layer, in some embodiments about 2 wt.% to about 45 wt.%, in some embodiments about 4 wt.% to about 40 wt.%, and in some embodiments about 5 wt.% to about 30 wt.%.
[0065] When multiple film layers are used, it is generally desired that each film layer includes a polymer matrix containing ethylene-vinyl acetate copolymer. In addition, each film layer may include multiple water-soluble particles distributed in the film polymer matrix containing ethylene-vinyl acetate copolymer. For example, the first film layer may include the first water-soluble particles distributed in the first film polymer matrix, and the second film layer may include the second water-soluble particles distributed in the second film polymer matrix. In these embodiments, the first polymer matrix and the second polymer matrix may each include ethylene-vinyl acetate copolymer. The water-soluble particles and ethylene-vinyl acetate copolymer in a film layer may be the same or different as those used in another film layer. In one embodiment, for example, the first film polymer matrix and the second film polymer matrix use the same ethylene-vinyl acetate copolymer, and the water-soluble particles in each layer have the same particle size and / or are formed by the same material. Similarly, the ethylene-vinyl acetate copolymer used in the film layer may also be the same or different as the hydrophobic polymer used in the core. In one embodiment, for example, the core and the film layer all use the same ethylene-vinyl acetate copolymer. In yet another embodiment, the film layer may employ an ethylene-vinyl acetate copolymer having a lower melt flow index than the hydrophobic polymer employed in the core. This may further help control the release of the therapeutic agent from the device, among other aspects. For example, the ratio of the melt flow index of the hydrophobic polymer used in the core to the melt flow index of the ethylene-vinyl acetate copolymer used in the film layer may be from about 1 to about 20, from about 2 to about 15 in some embodiments, and from about 4 to about 12 in some embodiments.
[0066] If desired, the membrane layer used in the device may optionally include a therapeutic agent, such as described below, which is also dispersed in the membrane polymer matrix. The therapeutic agent in the membrane layer may be the same or different from the therapeutic agent used in the core. When such a therapeutic agent is used in the membrane layer, the membrane layer generally includes an amount of therapeutic agent that makes the ratio of the concentration (wt.%) of the therapeutic agent in the core to the concentration (wt.%) of the therapeutic agent in the membrane layer greater than 1, about 1.5 or greater in some embodiments, and about 1.8 to about 4 in some embodiments. When used, the therapeutic agent generally only accounts for about 1wt.% to about 40wt.% of the membrane layer, about 5wt.% to about 35wt.% in some embodiments, and about 10wt.% to about 30wt.% in some embodiments. Of course, in other embodiments, before the therapeutic agent is released from the core, the membrane layer is substantially free of the therapeutic agent. When multiple film layers are used, each film layer can generally contain an amount of therapeutic agent such that the ratio of the weight percent of therapeutic agent in the core to the weight percent of therapeutic agent in the film layer is greater than 1, in some embodiments about 1.5 or greater, and in some embodiments from about 1.8 to about 4.
[0067] The film layer may also optionally include one or more excipients as described above, such as radiocontrast agents, fillers, plasticizers, surfactants, crosslinking agents, flow aids, colorants (e.g., chlorophyll, methylene blue, etc.), antioxidants, stabilizers, lubricants, other types of antimicrobial agents, preservatives, etc., to enhance performance and processability. When employed, optional excipients typically account for about 0.01wt.% to about 60wt.% of the film layer, and in some embodiments about 0.05wt.% to about 50wt.%, and in some embodiments about 0.1wt.% to about 40wt.%.
[0068] The film layer can be formed using the same or different technology as that used to form the core, such as by hot melt extrusion, compression molding (e.g., vacuum compression molding), injection molding, solvent casting, dip coating, spray coating, micro extrusion, cohesion, etc. In one embodiment, hot melt extrusion technology can be used. The core and the film layer can also be formed separately or simultaneously. In one embodiment, for example, the core and the film layer are formed separately, and then combined together using known bonding techniques, such as by stamping, heat sealing, adhesive bonding, etc. Compression molding (e.g., vacuum compression molding) can also be used to form an implantable device. As described above, the core and the film layer can be formed by heating and compressing the corresponding polymer into a desired shape under vacuum, respectively. Once formed, the core and the film layer can be stacked together to form a multilayer precursor, and then compression molding is performed as described above to form the resulting implantable device.
[0069] III. Sheath
[0070] If desired, the implantable device may also include a sheath disposed on at least a portion of the peripheral surface of the core (including any optional membrane layer disposed on the peripheral surface) so that the therapeutic agent can be released from the device primarily through the uncovered surface. In order to help control the release rate in this manner, the sheath may be formed by one or more layers comprising a sheath polymer matrix, which comprises a hydrophobic polymer. The sheath polymer matrix typically accounts for about 60wt.% to 100wt.%, in some embodiments about 70wt.% to 100wt.%, and in some embodiments about 90wt.% to 100wt.% (e.g., 100wt.%) of the sheath. The sheath is typically free of therapeutic agents, but if therapeutic agents are present, the therapeutic agent typically accounts for less than about 10wt.% of the sheath, in some embodiments less than about 5wt.%, and in some embodiments about 0.001wt.% to about 4wt.%.
[0071] The sheath polymer matrix can be formed by a single hydrophobic polymer or a blend of hydrophobic polymers. Examples of suitable hydrophobic polymers for use in sheath polymer matrices can include, for example, silicone polymers, polyolefins, polyvinyl chloride, polycarbonate, polysulfone, styrene-acrylonitrile copolymers, polyurethanes, silicone polyether-polyurethanes, polycarbonate-polyurethanes, silicone polycarbonate-polyurethanes, etc., and combinations thereof. In certain embodiments, the sheath polymer matrix can include semi-crystalline olefin copolymers. For example, as determined according to ASTM D3418-15, the melting temperature of such olefin copolymers can be, for example, at 20°C to about 100°C, in some embodiments from about 25°C to about 80°C, in some embodiments from about 30°C to about 70°C, in some embodiments from about 35°C to about 65°C, and in some embodiments from about 40°C to about 60°C. Such copolymers are generally derived from at least one olefin monomer (e.g., ethylene, propylene, etc.) and at least one polar monomer grafted onto the polymer backbone and / or incorporated as a constituent of a polymer (e.g., block or random copolymer). Suitable polar monomers include, for example, vinyl acetate, vinyl alcohol, maleic anhydride, maleic acid, (meth)acrylic acid (e.g., acrylic acid, methacrylic acid, etc.), (meth)acrylic acid esters (e.g., acrylic acid esters, methacrylic acid esters, ethyl acrylate, methyl methacrylate, ethyl methacrylate, etc.), etc. Various such copolymers can be generally used in the polymer composition, such as ethylene-vinyl acetate copolymers, ethylene-(meth)acrylic acid polymers (e.g., ethylene-acrylic acid copolymers and partially neutralized ionomers of these copolymers, ethylene-methacrylic acid copolymers and partially neutralized ionomers of these copolymers, etc.), ethylene-(meth)acrylic acid ester polymers (e.g., ethylene-methyl acrylate copolymers, ethylene-ethyl acrylate copolymers, ethylene-butyl acrylate copolymers, etc.), etc.
[0072] In a particular embodiment, the sheath polymer matrix may contain at least one ethylene-vinyl acetate polymer. When employed, certain aspects of the copolymer may be selectively controlled to help ensure that the sheath remains substantially impermeable to the therapeutic agent. For example, the vinyl acetate content of the copolymer may be selectively controlled within the range of about 10 wt.% to about 50 wt.%, in some embodiments about 15 wt.% to about 40 wt.%, in some embodiments about 20 wt.% to about 35 wt.%, and in some embodiments about 24 wt.% to about 32 wt.% of the copolymer. In fact, in some cases, the vinyl acetate content of the polymer in the core polymer matrix may be greater than the vinyl acetate content in the sheath polymer matrix, such that the ratio of the respective vinyl acetate contents is about 1 to about 2.5, in some embodiments about 1.2 to about 2, and in some embodiments about 1.4 to about 1.9. The ethylene content of the copolymer in the sheath polymer matrix may similarly be from about 50 wt.% to about 90 wt.%, in some embodiments from about 60 wt.% to about 85 wt.%, in some embodiments from about 65 wt.% to about 80 wt.%, and in some embodiments from about 68 wt.% to about 76 wt.%. The ethylene-vinyl acetate copolymer and the resulting sheath polymer matrix may also have a melt flow index of from about 0.2 g / 10 min to about 100 g / 10 min, in some embodiments from about 5 g / 10 min to about 90 g / 10 min, in some embodiments from about 10 g / 10 min to about 80 g / 10 min, and in some embodiments from about 30 g / 10 min to about 70 g / 10 min, as determined according to ASTM D1505-18 at a temperature of 190°C and a load of 2.16 kg. The ethylene-vinyl acetate copolymer may also have a density of about 0.900 grams per cubic centimeter (g / cm 3 ) to about 1.00g / cm 3 , in some embodiments about 0.910 g / cm 3 To about 0.980g / cm 3 , and in some embodiments about 0.940 g / cm 3 To about 0.970g / cm 3 Particularly suitable examples of ethylene-vinyl acetate copolymers that may be employed include those known under the names Those obtained from Celanese (e.g., 2861AC); by name Those obtained from Dow ( 240W); and Those available from Arkema (eg, EVATANE 28-40).
[0073] Sheath and any optional film layer can be formed using the same or different technology as that used to form the core, such as by hot melt extrusion, compression molding (e.g., vacuum compression molding), injection molding, solvent casting, dip coating, spray coating, micro extrusion, cohesion, etc. In one embodiment, hot melt extrusion technology can be used. The core, film and sheath can also be formed separately or simultaneously. In one embodiment, for example, the core, film and sheath are formed separately, and then combined together using known bonding techniques, such as by stamping, heat sealing, adhesive bonding, etc. Compression molding (e.g., vacuum compression molding) can also be used to form an implantable device. As described above, the core, film and sheath can be formed by heating and compressing the corresponding polymer into a desired shape under vacuum, respectively. Once formed, the core, film and sheath can be stacked together to form a multilayer precursor, and then compression molding is performed as described above to form the resulting implantable device.
[0074] IV. Device Configuration
[0075] See also Figure 1 to Figure 2 , for example, shows one embodiment of an implantable device 10. The implantable device 10 includes a core 40 having a generally circular cross-sectional shape and being elongated so that the resulting device is generally cylindrical in nature. During use of the device 10, the therapeutic agent can be released from the core 40 so that it is discharged from the outer surface 42 of the implantable device 10.
[0076] As shown in the figure, implantable device can have length (L) and cross-sectional diameter (D).Implantable device can have relatively small size.For example, cross-sectional diameter (D) can be about 0.1 millimeter to about 10 millimeters, about 0.1 millimeter to about 5 millimeters in some embodiments, about 0.3 millimeter to about 2 millimeters in some embodiments, and about 0.4 millimeter to about 0.8 millimeter in some embodiments.The length (L) of implantable device can change, but is generally about 1 millimeter to about 250 millimeters, about 2 millimeters to about 200 millimeters in some embodiments, about 10 millimeters to about 150 millimeters in some embodiments, and about 20 millimeters to about 100 millimeters in some embodiments.The device can be adjusted in size according to the therapeutic agent load and implantation time required.For example, for more lasting implant, size can be increased so that implant can load enough therapeutic agents to continue the life of implant.
[0077] Another embodiment of the implantable device 10 is as follows Figure 3 to Figure 4As shown. The core 40 has a generally circular cross-sectional shape and is elongated, so that the resulting device is generally cylindrical in nature. The core 40 defines an outer peripheral surface 61, and the membrane layer 20 is circumferentially disposed around the outer peripheral surface 61. Similar to the core 40, the membrane layer 20 also has a generally circular cross-sectional shape and is elongated to cover the entire length of the core 40. During use of the device 10, the therapeutic agent can be released from the core 40 and pass through the membrane layer 20, so that it is discharged from the outer surface 21 of the device.
[0078] Of course, in other embodiments, the device may include multiple membrane layers. Figure 3 to Figure 4 In the device, for example, one or more additional membrane layers (not shown) may be provided on the membrane layer 20 to help further control the release of the therapeutic agent. In other embodiments, the device may be configured such that the core is located or sandwiched between the various membrane layers.
[0079] The implantable device can have a variety of different geometric shapes, such as cylindrical (rod), disk, ring, circle, spiral, elliptical, triangular, oval, etc.
[0080] If necessary, the implantable device can be sealed in a package (e.g., a sterile blister package) before use. The material and manner of the package seal can vary, as known in the art. In one embodiment, for example, the package can include a substrate, and the substrate includes any number of layers required to achieve the desired level of protective performance, such as 1 layer or more layers, 1 layer to 4 layers in some embodiments, and 1 layer to 3 layers in some embodiments. Typically, the substrate includes a polymer film, such as those formed by polyolefins (e.g., ethylene copolymers, propylene copolymers, propylene homopolymers, etc.), polyesters (e.g., polyethylene terephthalate, polyethylene naphthalate, polybutylene terephthalate, etc.), vinyl chloride polymers (vinyl chloride polymers), vinyl chloride polymers (vinyl chloride polymers), ionomers, etc., and combinations thereof. One or more planes of the film can be sealed (e.g., heat-sealed) together, such as sealed together at the peripheral edge to form a cavity, in which the device can be stored. For example, a single film can be folded at one or more points and sealed along its periphery to define the cavity in which the device is located. To use the device, the package may be opened, such as by breaking a seal, and the device removed and implanted in a patient.
[0081] Without departing from the spirit and scope of the present invention, those of ordinary skill in the art may make these and other modifications and variations to the present invention. In addition, it should be understood that the various aspects of each embodiment may be fully interchangeable or partially interchangeable. In addition, those of ordinary skill in the art will appreciate that the foregoing description is exemplary only and is not intended to limit the present invention as further described in the appended claims.
Claims
1. A method for preventing and / or treating an eye disorder, the method comprising: include: An implantable device is inserted into the suprachoroidal space of an eye of a patient, wherein the implantable device includes a core defining a peripheral surface, wherein the core comprises a core polymer matrix comprising ethylene-vinyl acetate copolymer, and a therapeutic agent is dispersed within the core polymer matrix.
2. The method according to claim 1, in, The core is loaded with about 5 μg to about 100 mg of the therapeutic agent.
3. The method according to claim 1, in, The implantable device is inserted through a scleral incision formed to expose the suprachoroidal space.
4. The method according to claim 1, in, The needle delivers the implantable device to the suprachoroidal space.
5. The method according to claim 1, in, The implantable device is capable of releasing the therapeutic agent within the suprachoroidal space.
6. The method according to claim 1, in, The device is capable of releasing the therapeutic agent over a period of about 21 days or longer.
7. The method according to claim 1, in, The device is capable of releasing the therapeutic agent over a period of about 3 months or longer.
8. The method according to claim 1, in, The device is capable of releasing the therapeutic agent over a period of about 6 months or longer.
9. The method according to claim 1, in, The device is capable of releasing the therapeutic agent over a period of about 12 months or longer.
10. The method according to claim 1, in, The therapeutic agent is capable of being released from the device in a therapeutically effective amount.
11. The method according to claim 1, in, The eye disorder is age-related macular degeneration.
12. The method according to claim 1, in, The therapeutic agent comprises about 20 wt.% to about 70 wt.% of the core, and the core polymer matrix comprises about 30 wt.% to about 80 wt.% of the core.
13. The method according to claim 1, in, The ethylene-vinyl acetate copolymer has (i) a vinyl acetate monomer content of about 10 wt.% to about 60 wt.%, (ii) a melt flow index of about 0.2 g / 10 min to about 100 g / 10 min measured at a temperature of 190°C and a load of 2.16 kg according to ASTM D1238-20, and / or (iii) a melting temperature of about 20°C to about 70°C measured according to ASTM D3418-15.
14. The method according to claim 1, in, The therapeutic agent is a macromolecular compound having a molecular weight of about 1 kDa or greater.
15. The method according to claim 1, in, The therapeutic agent includes a protein, a peptide, an enzyme, an antibody, an interferon, an interleukin, a blood factor, a vaccine, a nucleotide, a lipid or an analog, a derivative or a combination thereof.
16. The method according to claim 1, in, The therapeutic agent is a small molecule compound having a molecular weight of less than about 1,000 Da.
17. The method according to claim 1, in, The therapeutic agents include tyrosine kinase inhibitors.
18. The method according to claim 17, in, The tyrosine kinase inhibitor includes axitinib, bosutinib, cabozantinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, ponatinib, ruxolitinib, sorafenib, sunitinib, vatalanib, vemurafenib or a combination thereof.
19. The method according to claim 1, in, The therapeutic agent includes a steroidal agent.
20. The method according to claim 19, in, The steroidal agent includes hydrocortisone, cortisone acetate, cortisone / cortisol, fluocortolone, fluocinolone, fluorometholone, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, paramethasone, derivatives thereof, or any combination of the foregoing.
21. The method according to claim 1, in, The core also includes a hydrophilic compound.
22. The method according to claim 1, in, The device also includes a membrane disposed on at least a portion of the peripheral surface.
23. The method according to claim 22, in, The film comprises a layer comprising water-soluble particles dispersed within a film polymer matrix, wherein the film polymer matrix comprises ethylene-vinyl acetate copolymer.
24. The method according to claim 1, in, The device has a generally circular cross-sectional shape.
25. The method according to claim 1, in, The device is cylindrical in shape.
26. The method according to claim 1, in, The cross-sectional diameter of the device is from about 0.01 mm to about 5 mm.
27. The method according to claim 1, in, The length of the device is from about 0.5 mm to about 25 mm.
